Colorectal cancer is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and improved surgery. Adjuvant chemotherapy is now considered the standard treatment for stage III colon cancer, and has evolved recently with the introduction of infusional, combination chemotherapy. Adjuvant therapy for stage II colon cancer has been more controversial. Recent trial data suggest, however, that there is a legitimate case for discussing the advantages and limitations with individual patients.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Faivre-Finn C et al. (2002) Colon cancer in France: evidence for improvement in management and survival. Gut 51: 60–64
Buyse M et al. (1988) Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571–3578
Moertel CG et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352–358
Moertel CG et al. (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13: 2936–2943
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939–944
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer J Clin Oncol 17: 1356–1363
Haller DG et al. (1998) Flurouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Five year final report of INT-0089 [abstract]. Proc Am Soc Clin Oncol 17: a256
QUASAR Collaborative Group (2000) Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial Lancet 355: 1588–1596
Cassidy J et al. (2004) Capecitabine versus bolus 5FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial [abstract]. Proc Am Soc Clin Oncol 23: a3509
Andre T et al. (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896–2903
Saini A et al. (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88: 1859–1865
Andre T et al. (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer. N Engl J Med 350: 2343–2351
Saltz LB et al. (2004) Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) [abstract]. J Clin Oncol 22 (Suppl): a246
Van Cutsem E et al. (2005) Randomised phase III trial comparing infused irinotecan/5-flurouracil/folinic acid versus 5FU/FA in stage III colon cancer patients (PETACC III) [abstract]. Proc Am Soc Clin Oncol
Mamounas E et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349–1355
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356–1363
Gill S et al. (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797–1806
Benson AB III et al. (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408–3419
Kerr DJ et al. (2000) Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules—less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann Oncol 11: 947–955
Gray RG et al. for the QUASAR Collaborative Group. (2004) QUASAR: A randomized study of adjuvant chemotherapy versus observation including 3238 colorectal cancer patients [abstract]. J Clin Oncol 22 (Suppl): aS3501
Hawkins N et al. (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376–1387
Witzig TE et al. (1991) DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68: 879–888
Zhou W et al. (2001) Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol 19: 78–81
Khan ZA et al. (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res 6: 3499–3504
Wang Y et al. (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22: 1564–1571
Saltz LB et al. (2004) Irinotecan plus fluorouracil/leucovorin versus fluorouracil/leucovorin alone in stage III colon cancer. Proc Am Soc Clin Oncol 23: a3500
The authors declare no competing financial interests.
International Multicentre Pooled Analysis of Colon Cancer Trials
QUick And Simple And Reliable
Xeloda in Adjuvant Colon Cancer Therapy
Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer
Pan-European Trials in Adjuvant Colon Cancer
National Surgical Adjuvant Breast and Bowel Project
About this article
Cite this article
Midgley, R., Kerr, D. Adjuvant chemotherapy for stage II colorectal cancer: the time is right!. Nat Rev Clin Oncol 2, 364–369 (2005). https://doi.org/10.1038/ncponc0228
Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer
Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer
Gastrointestinal Endoscopy (2018)
Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns
NeuroImage: Clinical (2017)
Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: A promising in vivo drug delivery system for colorectal cancer therapy
European Journal of Medicinal Chemistry (2017)